How to respond to CRISPR babies
By Editorial,
Nature
| 12. 05. 2018
People like to say that science is self-correcting. Events in China last week pose a serious challenge to that reassuring platitude. How do researchers respond to the failure of medical ethics, collective responsibility and professional standards that saw an immature experimental technique used to help produce human babies?
It has not yet been independently confirmed that the Chinese genome-editing researcher He Jiankui altered the DNA of embryos using a gene-editing technique and then implanted them in a woman, as he claims. Such a step would be significant and controversial because it would make a permanent change to the germ line that could be passed on to future generations. (This distinguishes germline editing from the use of gene-editing tools as therapies that correct genetic alterations in somatic cells in blood and other tissues.)
Verification of He’s claims could be difficult, given that privacy concerns rightly protect the identity of the parents and their one-month-old twin girls. But many scientists in the field agree on two things: the relative simplicity and widespread availability of the gene-editing tool CRISPR–Cas9 mean that what He...
Related Articles
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Nick Paul Taylor, Fierce Biotech | 01.09.2026
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist Fyodor Urnov, Ph.D., to launch Aurora...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...